Generation Investment Management LLP Has $475.29 Million Stock Holdings in Becton, Dickinson and Company $BDX

Generation Investment Management LLP reduced its stake in Becton, Dickinson and Company (NYSE:BDX) by 47.9% in the 2nd quarter, HoldingsChannel reports. The firm owned 2,759,307 shares of the medical instruments supplier’s stock after selling 2,537,140 shares during the quarter. Becton, Dickinson and Company makes up 3.0% of Generation Investment Management LLP’s portfolio, making the stock its 15th biggest position. Generation Investment Management LLP’s holdings in Becton, Dickinson and Company were worth $475,291,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Saudi Central Bank acquired a new position in Becton, Dickinson and Company during the 1st quarter worth approximately $26,000. Kelly Lawrence W & Associates Inc. CA bought a new stake in shares of Becton, Dickinson and Company during the first quarter valued at approximately $31,000. Bank of Jackson Hole Trust raised its position in shares of Becton, Dickinson and Company by 85.6% during the second quarter. Bank of Jackson Hole Trust now owns 206 shares of the medical instruments supplier’s stock worth $35,000 after purchasing an additional 95 shares during the period. WPG Advisers LLC bought a new position in shares of Becton, Dickinson and Company in the 1st quarter worth $36,000. Finally, CVA Family Office LLC grew its position in Becton, Dickinson and Company by 79.5% in the 2nd quarter. CVA Family Office LLC now owns 219 shares of the medical instruments supplier’s stock valued at $38,000 after purchasing an additional 97 shares during the period. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Claire Fraser sold 917 shares of the business’s stock in a transaction dated Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Bertram L. Scott sold 217 shares of the firm’s stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $176.58, for a total transaction of $38,317.86. Following the sale, the director owned 35,816 shares of the company’s stock, valued at approximately $6,324,389.28. The trade was a 0.60% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 1,249 shares of company stock worth $231,358 over the last three months. 0.36% of the stock is owned by insiders.

Analysts Set New Price Targets

Several research analysts have weighed in on BDX shares. Morgan Stanley upped their price objective on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Royal Bank Of Canada lowered their target price on shares of Becton, Dickinson and Company from $211.00 to $202.00 and set a “sector perform” rating on the stock in a report on Friday. Wall Street Zen downgraded Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Saturday. Stifel Nicolaus lowered their price objective on Becton, Dickinson and Company from $224.00 to $210.00 in a research note on Friday. Finally, Piper Sandler cut their target price on Becton, Dickinson and Company from $200.00 to $190.00 and set a “neutral” rating on the stock in a research report on Friday. Three investment analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, Becton, Dickinson and Company currently has a consensus rating of “Hold” and a consensus target price of $203.27.

Becton, Dickinson and Company Price Performance

Becton, Dickinson and Company stock opened at $177.88 on Monday. Becton, Dickinson and Company has a 52 week low of $162.29 and a 52 week high of $251.99. The company’s 50 day moving average price is $186.77 and its two-hundred day moving average price is $182.15. The company has a quick ratio of 0.62, a current ratio of 1.10 and a debt-to-equity ratio of 0.69. The stock has a market cap of $50.99 billion, a P/E ratio of 31.99, a P/E/G ratio of 1.42 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX) last released its earnings results on Thursday, April 14th. The medical instruments supplier reported $4.10 earnings per share (EPS) for the quarter. The company had revenue of $5.32 billion during the quarter. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%. On average, equities analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 31st. Stockholders of record on Monday, December 8th will be given a dividend of $1.05 per share. The ex-dividend date of this dividend is Monday, December 8th. This represents a $4.20 annualized dividend and a dividend yield of 2.4%. This is a boost from Becton, Dickinson and Company’s previous quarterly dividend of $1.04. Becton, Dickinson and Company’s payout ratio is 71.36%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.